PAVmed Provides Business Update and Third Quarter 2024 Financial Results

Go back to PAVmed Provides Business Update and Third Quarter 2024 Financial Results

Lucid Diagnostics Inc (LUCD) PT Lowered to $2 at Cantor Fitzgerald

November 15, 2024 6:41 AM EST

Cantor Fitzgerald analyst Ross Osborn lowered the price target on Lucid Diagnostics Inc (NASDAQ: LUCD) to $2.00 (from $3.00) while maintaining a Overweight rating.

The analyst comments "We are lowering our price target to $2 from $3 as the company is still working through the process of receiving... More